Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
there is too much stock out there.
no real investor relation support
i bet there is going to be ahuge reverse split coming
100:1
his stock is going to 0
POSC submitted 510(K) for its Attrius Pet scanner on January 28. There should be a decision and an announcement since it has been 90 days.
if it is a yes the stock should go flying
crossing my fingers.
Do you people realize there is $450 dollars of buying today?
still waiting on the big move.........wait for it....wait for it..............
haha
POSC to be featured on WallSteet.net next week
oh yeah, its just running away.
lol
FDA approval is expected by April 29th or sooner since the sucbmission for thr PET was submitted on January 29th. FDA has 90 days or less to issue the statement. Should be a major move in the stock on that news.
LOAD UP ON POSC before the run!
not a buy...read the footnote
Explanation of Responses:
( 1) The Company and the Williams, on March 6, 2009, agreed to modify the Warrant to extend the expiration date to February 16, 2012 in exchange for the William's agreement to extend their guaranty of the Company's indebtedness pursuant to a line of credit.
Positron places bets on PET-only Attrius system
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Positron has had its ups and downs, to say the least, over the past decade, but the PET device developer thinks it now has a strategy and product to become a more prominent player in the nuclear medicine market.
Fishers, IN-based Positron is banking on the appeal of Attrius, its PET-only device designed for cardiac imaging at community and rural hospitals as well as cardiology practices.
Positron's Attrius cardiac PET scanner. Image courtesy of Positron.
Attrius and the novel strategy behind it are the brainchild of Positron president Joseph Oliverio and medical director Dr. Michael Merhige. Merhige came from a cardiac group in Buffalo, NY, which began using cardiac PET imaging in an outpatient setting in 1995, around the time Medicare began to reimburse for such scans.
In 2003, the pair was recruited by a community hospital in Niagara County, NY, which had one of the worst coronary disease death rates per county in the U.S. Like many community hospitals in the country, the facility had a difficult time competing against larger tertiary care centers, Oliverio said, and didn't have a unique cardiovascular offering to stop the migration of patients to other facilities, or to attract patients from other hospitals.
With the help of cardiac PET, the facility was successful in reducing the heart attack and cardiac death rate in the county, as well as the number of angiograms that were being performed, by providing a more accurate diagnosis of cardiac disease through PET, Oliverio said.
Bucking the PET/CT wave
Oliverio acknowledges that the strategy bucks the popularity of PET/CT systems among healthcare facilities. A recent report by market research firm IMV Medical Information Division of Des Plaines, IL, found that no PET-only scanners were installed in the U.S. in 2008; PET-only devices made up 3% of the total installed in 2007 and 60% of systems installed in 2001.
"Everything is going PET/CT, but I didn't see the value in having a combination PET/CT device for cardiovascular use," he said. "There is the benefit of a CT angiogram with PET perfusion, but I am not buying the argument that it needs to be in the same setting. I understand with oncology there is a great benefit in having the patient on the same [PET/CT] table, but with cardiovascular imaging, I didn't see the economic benefit or the clinical benefit."
So, with the expiration of some patents, Positron set out to design and manufacture a less expensive PET-only camera for the community hospital and cardiologist office market. The first key step was to partner with Neusoft Medical Systems of Shenyang, China, starting in January 2006, to begin the manufacture of a PET-only system.
Positron submitted its 510(k) clearance application for Attrius to the U.S. Food and Drug Administration (FDA) in January. Once cleared, the company could begin marketing the device in the U.S. this year.
Oliverio said the Neusoft Positron Medical Systems joint venture could produce as many as 50 PET-only systems per month, if necessary. Positron has exclusive marketing rights for Attrius in the U.S., while Neusoft has exclusivity in China. The two companies share marketing rights in the rest of the world.
Price point
Oliverio did not offer a specific price for Attrius, other than to say it is "priced significantly less than cardiologists' choices for new PET/CT scanners."
The device offers a coronary disease quantitative software package written by cardiac PET pioneer Dr. K. Lance Gould from the University of Texas Medical School at Houston. In addition, Positron plans to offer ejection fraction analysis and CT angiography fusion with PET data through third-party software.
Oliverio is optimistic that Attrius will be well received by healthcare providers looking for a cardiology niche. "We know that the cardiac PET market is expanding, primarily because we see large and mid-sized pharmaceutical companies trying to develop a single-dose F-18-based cardiac perfusion agent," he said. "They wouldn't be developing it if they didn't feel the market wasn't going to flourish."
Positron also has been in contact with Bracco Diagnostics of Princeton, NJ, which markets the PET radiopharmaceutical CardioGen-82 (rubidium Rb 82 generator), the only generator-based PET cardiac perfusion agent approved by the FDA and reimbursed for coronary artery disease evaluation.
"We have been in close contact with them and they have reassured us that there is a significant demand for [a PET-only cardiac system]," Oliverio said.
PET's efficacy
Previous research also would appear to support the efficacy of cardiac PET. Researchers from the State University of New York at Buffalo, led by Merhige, found that the use of PET myocardial perfusion imaging with rubidium-82 in patients with intermediate coronary artery disease resulted in a greater than 50% reduction in invasive coronary arteriography and coronary artery bypass graft surgery.
Merhige, who also serves as director of the Heart Center of Niagara in Niagara Falls, NY, and colleagues also wrote that there was a 30% cost savings by avoiding additional procedures, and patients experienced "excellent clinical outcomes at one year compared with SPECT" (Journal of Nuclear Medicine, July 2007, Vol. 48:7, pp. 1069-1076).
Marketing strategy
Positron currently is establishing marketing and distribution channels, with cardiology offices as "the primary target," Oliverio said. "However, I believe the largest societal benefit of this technology will be through placing these systems within the rural hospital market."
Positron also created a program called PosiRx to give imaging providers the choice of radiopharmaceuticals, dispensing systems, molecular imaging devices, and equipment service directly from the company. Positron will offer distribution and dose dispensing of radiopharmaceuticals through its Nuclear Pharm-Assist device.
With the U.S. economy currently in dire straits, limiting the ability of many hospitals to pursue new capital equipment purchases, Positron also is looking to partner with a financing company to stimulate the PET market.
"With cardiac PET, it is known that it will have a clinical benefit if it is put into practice," Oliverio said. "At the same time, the ability to monitor therapy and take advantage of the trends of medicine going toward proactive, nonsurgical methods, and the ability to track coronary disease progression, reversal, or cessation of disease, is priceless, in my opinion."
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Related Reading
Neusoft Positron files 510(k) for Attrius, January 29, 2009
Positron launches cardiac nuclear medicine package, January 9, 2009
Positron hires medical director, December 17, 2008
Neusoft taps TUV for FDA help, October 23, 2007
Positron opens Chinese joint venture, February 13, 2006
Copyright © 2009 AuntMinnie.com
Positron places bets on PET-only Attrius system
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Positron has had its ups and downs, to say the least, over the past decade, but the PET device developer thinks it now has a strategy and product to become a more prominent player in the nuclear medicine market.
Fishers, IN-based Positron is banking on the appeal of Attrius, its PET-only device designed for cardiac imaging at community and rural hospitals as well as cardiology practices.
Positron's Attrius cardiac PET scanner. Image courtesy of Positron.
Attrius and the novel strategy behind it are the brainchild of Positron president Joseph Oliverio and medical director Dr. Michael Merhige. Merhige came from a cardiac group in Buffalo, NY, which began using cardiac PET imaging in an outpatient setting in 1995, around the time Medicare began to reimburse for such scans.
In 2003, the pair was recruited by a community hospital in Niagara County, NY, which had one of the worst coronary disease death rates per county in the U.S. Like many community hospitals in the country, the facility had a difficult time competing against larger tertiary care centers, Oliverio said, and didn't have a unique cardiovascular offering to stop the migration of patients to other facilities, or to attract patients from other hospitals.
With the help of cardiac PET, the facility was successful in reducing the heart attack and cardiac death rate in the county, as well as the number of angiograms that were being performed, by providing a more accurate diagnosis of cardiac disease through PET, Oliverio said.
Bucking the PET/CT wave
Oliverio acknowledges that the strategy bucks the popularity of PET/CT systems among healthcare facilities. A recent report by market research firm IMV Medical Information Division of Des Plaines, IL, found that no PET-only scanners were installed in the U.S. in 2008; PET-only devices made up 3% of the total installed in 2007 and 60% of systems installed in 2001.
"Everything is going PET/CT, but I didn't see the value in having a combination PET/CT device for cardiovascular use," he said. "There is the benefit of a CT angiogram with PET perfusion, but I am not buying the argument that it needs to be in the same setting. I understand with oncology there is a great benefit in having the patient on the same [PET/CT] table, but with cardiovascular imaging, I didn't see the economic benefit or the clinical benefit."
So, with the expiration of some patents, Positron set out to design and manufacture a less expensive PET-only camera for the community hospital and cardiologist office market. The first key step was to partner with Neusoft Medical Systems of Shenyang, China, starting in January 2006, to begin the manufacture of a PET-only system.
Positron submitted its 510(k) clearance application for Attrius to the U.S. Food and Drug Administration (FDA) in January. Once cleared, the company could begin marketing the device in the U.S. this year.
Oliverio said the Neusoft Positron Medical Systems joint venture could produce as many as 50 PET-only systems per month, if necessary. Positron has exclusive marketing rights for Attrius in the U.S., while Neusoft has exclusivity in China. The two companies share marketing rights in the rest of the world.
Price point
Oliverio did not offer a specific price for Attrius, other than to say it is "priced significantly less than cardiologists' choices for new PET/CT scanners."
The device offers a coronary disease quantitative software package written by cardiac PET pioneer Dr. K. Lance Gould from the University of Texas Medical School at Houston. In addition, Positron plans to offer ejection fraction analysis and CT angiography fusion with PET data through third-party software.
Oliverio is optimistic that Attrius will be well received by healthcare providers looking for a cardiology niche. "We know that the cardiac PET market is expanding, primarily because we see large and mid-sized pharmaceutical companies trying to develop a single-dose F-18-based cardiac perfusion agent," he said. "They wouldn't be developing it if they didn't feel the market wasn't going to flourish."
Positron also has been in contact with Bracco Diagnostics of Princeton, NJ, which markets the PET radiopharmaceutical CardioGen-82 (rubidium Rb 82 generator), the only generator-based PET cardiac perfusion agent approved by the FDA and reimbursed for coronary artery disease evaluation.
"We have been in close contact with them and they have reassured us that there is a significant demand for [a PET-only cardiac system]," Oliverio said.
PET's efficacy
Previous research also would appear to support the efficacy of cardiac PET. Researchers from the State University of New York at Buffalo, led by Merhige, found that the use of PET myocardial perfusion imaging with rubidium-82 in patients with intermediate coronary artery disease resulted in a greater than 50% reduction in invasive coronary arteriography and coronary artery bypass graft surgery.
Merhige, who also serves as director of the Heart Center of Niagara in Niagara Falls, NY, and colleagues also wrote that there was a 30% cost savings by avoiding additional procedures, and patients experienced "excellent clinical outcomes at one year compared with SPECT" (Journal of Nuclear Medicine, July 2007, Vol. 48:7, pp. 1069-1076).
Marketing strategy
Positron currently is establishing marketing and distribution channels, with cardiology offices as "the primary target," Oliverio said. "However, I believe the largest societal benefit of this technology will be through placing these systems within the rural hospital market."
Positron also created a program called PosiRx to give imaging providers the choice of radiopharmaceuticals, dispensing systems, molecular imaging devices, and equipment service directly from the company. Positron will offer distribution and dose dispensing of radiopharmaceuticals through its Nuclear Pharm-Assist device.
With the U.S. economy currently in dire straits, limiting the ability of many hospitals to pursue new capital equipment purchases, Positron also is looking to partner with a financing company to stimulate the PET market.
"With cardiac PET, it is known that it will have a clinical benefit if it is put into practice," Oliverio said. "At the same time, the ability to monitor therapy and take advantage of the trends of medicine going toward proactive, nonsurgical methods, and the ability to track coronary disease progression, reversal, or cessation of disease, is priceless, in my opinion."
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Related Reading
Neusoft Positron files 510(k) for Attrius, January 29, 2009
Positron launches cardiac nuclear medicine package, January 9, 2009
Positron hires medical director, December 17, 2008
Neusoft taps TUV for FDA help, October 23, 2007
Positron opens Chinese joint venture, February 13, 2006
Copyright © 2009 AuntMinnie.com
stay tuned and I will have some info.
what do you mean add you? as an assitant?
Positron's Portable Injection System, Tech-Assist Reduced Radiation Exposure by 50%-75%
Tuesday March 3, 10:39 am ET
INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News), a Cardiac Molecular Imaging Solutions Company, announced today the results from an independent study on radiation exposure of technologists administering FDG. The study was conducted in the Nuclear Medicine Department at Mount Sinai Medical Center in New York, N.Y. by the Director of PET, Ash Rafique. The study compared historic whole body and ring readings using a traditional syringe shield compared to Positron’s Tech-Assist™ device. The results showed a reduction in whole body badge exposure by 50%-75% and ring badge reductions of 40%-55%, compared to previous month’s data.
Positron’s Tech-Assist™ is a heavy duty syringe shield (PIG) mounted on a portable cart system. This system is designed to reduce or limit exposure, heavy lifting injuries and repetitive motion injuries that occur during Nuclear Medicine injection applications. The Tech-Assist™ was designed with the ALARA principles of Time, Distance, and Shielding in mind. The Tech-Assist™ utilizes tungsten for all shielding. The cart enables the user to transport the PIG to and from the injection room with ease and adjusts to various height levels allowing for the injection of ambulatory or supine patients. . The variable injection head rotates 360° allowing for left or right arm injections and hinges to four different angles creating multiple loading or injecting positions. In additional to significant reduction in radiation exposure the Tech-Assist™ will improve the comfort and ease of the injection process for the patient as well as for the technologist/nurse.
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers the world’s first robotic systems (Nuclear Pharm-Assis® & Cardio-Assist™) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius™) and SPECT cameras (Pulse®);. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Contact:
Positron Corporation
Joseph Oliverio, (866)613-7587
--------------------------------------------------------------------------------
Source: Positron Corporation
looks like POSC is cleaned up. Nice bid suppport and trading at .03
Awesome news out on POSC
Press Release Source: Positron Corporation
Positron Corporations Joint Venture Submits FDA 510(k) for its Attrius PET Scanner
Wednesday January 28, 2009, 1:22 pm EST
INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News), a Cardiac Molecular Imaging Solutions Company, announced today that the United States Food and Drug Administration (FDA) has received 510(k) submission for the Company’s jointly developed Attrius™ Positron Emission Tomography (PET) scanner product line. This is the first in a series of nuclear imaging products Positron plans to develop through its joint venture Neusoft Positron Medical Systems, based in Shenyang, China. Positron’s Attrius™ is a cardiac specific PET only device that competes with other cardiac imaging modalities with its superior quantification capabilities and disease management software all at an attractive price point.
Joseph Oliverio, President of Positron states that "This 510(k) submission is a significant milestone for Positron. Through our joint venture Neusoft Positron Medical Systems we have developed a state of the PET scanner in the Attrius™ that adds great value to our company and our nuclear cardiology product solutions.” Oliverio also stated, “The industry has seen an increasing market demand for cardiac PET. This increase stems from favourable reimbursement compared to other imaging modalities combined with its improved diagnostic accuracy. Positron’s Attrius™ PET scanner is the solution that thousands of cardiology groups are looking for to improve their bottom line, reduce healthcare costs and provide patients with a superior diagnosis of coronary artery disease. We believe that we can meet and expand the existing market demand with the Attrius™.”
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers world’s first robotic systems (Nuclear Pharm-Assis® & Cardio-Assist™) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius™) and SPECT cameras (Pulse®);. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (866)-613-7587
Contact:
Positron Corporation
Joseph Oliverio, President
(866) 613-7587
Share Statistics
Average Volume (3 month)3: 7,725
Average Volume (10 day)3: 43,528.6
Shares Outstanding5: 174.77M
Float: 57.17M
I would love to see what happens when some good news comes out and there is an audience.
great earning play potential!
Eagle Ford Shale play nearby could be of interest!!
stay tuned
VEDO CEO interview from 11/25/08
here is the link:
http://tv.wallst.net/r/3-minute-press/Mason-Conner/354/1418/
Recent financial news
VillageEDOCS Reports Record Net Profit on 19% Revenue Increase in Third Quarter Ended September 30, 2008
Nov 18, 2008 8:30:00 AM
View Additional ProfilesSANTA ANA, CA -- (MARKET WIRE) -- 11/18/08 -- VillageEDOCS, Inc. (OTCBB: VEDO), a Solution as a Service (SaaS) company, which is the largest segment of the Software as a Service (SaaS) market, achieved a record net profit of $318,800, on 19% growth in revenue to a record $4.27 million for the third quarter ended September 30, 2008, it was announced today by Mason Conner, Chief Executive Officer.
I have been following this company for 2 years. I think they are going to come out of the blocks with news and information soon.
press releases so far have been few and far between.
but some good info in them
How do you correct or edit old or wrong information in the stock profile in the ibox?
thanks
Positron Announces PosiRx Program for a Total Solution in Cardiac Nuclear Medicine
Thursday January 8, 3:42 pm ET
HOUSTON--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News) announced today that they will market its complete turnkey offering of radiopharmaceuticals, camera service and imaging for a total solution to customers under the name PosiRx™. Positron’s PosiRx™ will offer financing and partnership flexibility by providing imaging providers the choice of radiopharmaceuticals, radiopharmaceutical dispensing systems, molecular imaging devices, and equipment service directly from Positron. Customers can choose all services as a complete package or individual parts that suit their needs. Positron is able to offer innovative distribution and dose dispensing of radiopharmaceuticals directly to imaging providers as a result of their cutting edge “virtual pharmacy” device named the Nuclear Pharm-Assist®.
Positron’s President, Joseph Oliverio stated, “We are addressing the needs of physicians in these challenging economic times by providing them with patient and business flexibility combined with cost effective imaging provision alternatives.” Oliverio also went on to state, “that our new PosiRx™ solution will set a new industry standard for the distribution of radiopharmaceuticals giving Positron a significant market share in the massive radiopharmaceutical and imaging device market.”
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products. The Molecular Imaging Devices segment provides Positron Emission Tomography (PET) scanners and Single Photon Emission Computed Tomography (SPECT) cameras; the Radiopharmaceutical Products segment offers world’s first robotic systems for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases. The Company is able to offer a total customer solution which includes molecular imaging devices, disease specific software, radiopharmaceutical distribution and delivery systems, and radiopharmaceuticals agents for Cardiac Nuclear Medicine. Positron Corporation was incorporated in 1983 and is currently headquartered in Houston, Texas. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (281) 492-7100.
recent selling could be this loser from Shazam stocks that did nothing and had stock freed up
Positron Delivers SPECT Based Automated Radiopharmaceutical Dose Dispensing Unit to South American Nuclear Pharmacy Dec 19, 2008 11:26:00 AM Copyright Business Wire 2008 HOUSTON--(BUSINESS WIRE)-- Positron Corporation (POSC.OB) announced today that it has completed the sale and delivery of its SPECT based Nuclear Pharm-AssistTM device to Comci, LTDA in Bogota, Colombia. The Nuclear Pharm-AssistTM is an automated dose dispensing machine sold to pharmacies and healthcare providers designed to increase productivity, decrease or eliminate exposure issues while offering a platform for USP-797 and regulatory compliance. The Nuclear Pharm-AssistTM streamlines the production and delivery of radiopharmaceuticals allowing for the establishment of unique distribution models within the Nuclear Medicine market. "We are delighted to work with Comci on our state of the art SPECT based Nuclear Pharm-AssistTM," said Joe Oliverio, President of Positron. "Our automated dose dispensing technology enables Positron to be more integrated around the sale and distribution of radiopharmaceuticals to our customers."
POSC delivers Pharm-Assist to Bogota
Positron Delivers SPECT Based Automated Radiopharmaceutical Dose Dispensing Unit to South American Nuclear Pharmacy
Friday December 19, 11:26 am ET
HOUSTON--(BUSINESS WIRE)--Positron Corporation (POSC.OB) announced today that it has completed the sale and delivery of its SPECT based Nuclear Pharm-AssistTM device to Comci, LTDA in Bogota, Colombia.
The Nuclear Pharm-AssistTM is an automated dose dispensing machine sold to pharmacies and healthcare providers designed to increase productivity, decrease or eliminate exposure issues while offering a platform for USP-797 and regulatory compliance. The Nuclear Pharm-AssistTM streamlines the production and delivery of radiopharmaceuticals allowing for the establishment of unique distribution models within the Nuclear Medicine market.
“We are delighted to work with Comci on our state of the art SPECT based Nuclear Pharm-AssistTM,” said Joe Oliverio, President of Positron. “Our automated dose dispensing technology enables Positron to be more integrated around the sale and distribution of radiopharmaceuticals to our customers.”
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products. The Molecular Imaging Devices segment provides Positron Emission Tomography (PET) scanners and Single Photon Emission Computed Tomography (SPECT) cameras; the Radiopharmaceutical Products segment offers world’s first robotic systems for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases. The Company is able to offer a total customer solution which includes molecular imaging devices, disease specific software, radiopharmaceutical distribution and delivery systems, and radiopharmaceuticals agents for Cardiac Nuclear Medicine. Positron Corporation was incorporated in 1983 and is currently headquartered in Houston, Texas. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
NEWS OUT ON POSC
Positron Corporation Announces Appointment of Medical Director
Dec 16, 2008 4:21:00 PM
--(BUSINESS WIRE)-- Positron Corporation (OTC BB:POSC). Positron Corporation's Board of Directors has appointed Michael E. Merhige, M.D. as their Medical Director. Dr. Merhige will be responsible for providing clinical leadership and has designated his practice as a signature show site for Positron software developers and customers. Dr. Merhige has performed and interpreted over 25,000 cardiac PET scans, and has been involved in cardiac PET for 22 years. He is currently Director of the Heart Center of Niagara, which specializes in the noninvasive management of coronary disease guided by PET myocardial perfusion imaging. He has authored numerous publications in the field of cardiac molecular imaging, and is an acknowledged expert in the field.
Dr. Merhige said: "I am delighted to accept the position of Medical Director for Positron Corporation and to work closely with Positron's President, Joseph Oliverio. I have long noted that Positron equipment provides the best cardiac perfusion images using Rb-82, as well as the best cardiac software. I anticipate with the upcoming release of Positron's cost effective PET only alternative that cardiac PET will become the procedure of choice for managing patients with coronary disease because of its cost efficacy when compared to conventional SPECT imaging. My practice has noted a significant reduction in the utilization of subsequent coronary angiograms and bypass surgery, reduction in coronary disease management costs, and equivalent or better rates of outcomes when PET is used in place of SPECT imaging, with Positron equipment. "
Mr. Oliverio President of Positron said, "Dr. Merhige brings an essential clinical understanding of PET to Positron and will help us position our products to be widely accepted in the world markets. The addition of his site as our premier demonstration project will serve as an excellent example of the potential efficacy of PET in a rural hospital setting"
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products. The Molecular Imaging Devices segment provides PET scanners and SPECT cameras; the Pharmaceutical Products segment offers world's first robotic systems for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases. The Company is able to offer a total customer solution which includes low cost molecular imaging devices, disease specific software, radiopharmaceutical distribution and delivery systems, and radiopharmaceuticals agents for Cardiac Nuclear Medicine. Additional information can be found at http://www.positron.com
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Source: Positron Corporation
----------------------------------------------
Positron Corporation
Joe Oliverio
President
281-492-7100
bid support starting to come in.
get ready for a new IR effort
Here is alink to the company website which had the upcoming tradeshow schedule.
http://www.positron.com/index.shtml
Anyone have any recent news on POSC
Are you people still watching this stock?
pump and dump over so soon?
no news and the stock runs like that?
LOL
Authorized : 90,000,000
Outstanding: 34,000,000
you crack me up puppman
ARUR Announces Oil Sales
Aug 13, 2008 1:24:00 PM
View Additional ProfilesLEWISVILLE, TX -- (MARKET WIRE) -- 08/13/08 -- American Resource Technologies, Inc. (PINKSHEETS: ARUR) has been informed by the operator that by putting two new wells on line in July, oil sales increased more than 100% from June. With four new wells being brought to production during this month the Company expects to see this continued growth in its oil sales.
About American Resource Technologies, Inc.
The company is based in Lewisville, Texas. Additional information about the Company is available at www.arur.us
Where this statement includes "forward-looking" statements within the meaning of Section 27A of the Securities Act, the Company desires to take advantage of the "safe harbor" provisions thereof. Therefore, the Company is including this statement for the express purpose of availing itself of the protections of such safe harbor provisions with respect to all of such forward-looking statements. The forward-looking statements in this announcement reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ from those anticipated. In this announcement, the words "anticipates," "believes", "expects," "intends," "future" and similar expressions identify forward-looking statements. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that may arise after the date hereof. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this statement.
Contact:
M. H. McIlvain
972 219-8585
ARUR announces results of well test
American Resource Technologies, Inc. Announces Test Data on the Linn 1-08
Aug 7, 2008 1:36:00 PM
View Additional ProfilesLEWISVILLE, TX -- (MARKET WIRE) -- 08/07/08 -- American Resource Technologies, Inc. (PINKSHEETS: ARUR) has been informed by the operator that the initial swab testing of the Linn 1-08 located in Montgomery County, Kansas has been completed. The result from three fifteen-minute swabs was the recovery of approximately 4 barrels of fluid per hour with an oil cut of approximately 30%. While swab tests do not necessarily result in actual production, this recovery indicates that the well may be able to produce in excess of 100 barrels of fluid per day and if the oil-water ratio remains constant the well could produce in excess 30 barrels of oil per day. The Company is pleased and encouraged by these results.
About American Resource Technologies, Inc.
The company is based in Lewisville, Texas. Additional information about the Company is available at www.arur.us
Where this statement includes "forward-looking" statements within the meaning of Section 27A of the Securities Act, the Company desires to take advantage of the "safe harbor" provisions thereof. Therefore, the Company is including this statement for the express purpose of availing itself of the protections of such safe harbor provisions with respect to all of such forward-looking statements. The forward-looking statements in this announcement reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ from those anticipated. In this announcement, the words "anticipates," "believes, "expects," "intends," "future" and similar expressions identify forward-looking statements. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that may arise after the date hereof. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this statement.
Contact:
M. H. McIlvain
972 219-8585
you follow stocks you don't own and bash them?
some real news would be a nice catalyst here